Chemistry (Chemistry VC)

Seed and Series A firm; founded 2024, San Francisco. $350M Fund I (first and only fund to date). Three founding/managing partners: Mark Goldberg (ex-Index Ventures), Kristina Shen (ex-a16z 4y, ex-Bessemer 7y), Ethan Kurzweil (ex-Bessemer 16y). Notable portfolio: Decagon, Granola, Plaid, HashiCorp, Pave, Tennr, Datacurve.

Serval Relevance

• Participated in Serval’s $47M Series A (Oct 2025).
• Deal partner: Kristina Shen ^[strongly inferred] — Serval listed in her personal portfolio on the Chemistry team page alongside Decagon, Pave, ServiceTitan, Sprig, Tennr. She has a strong AI-applications track record from her a16z days (Sprig, Decagon).
• Chemistry’s portfolio listing for Serval: “Replacing legacy help desks with an AI-native ITSM platform, letting teams handle provisioning and support directly in Slack, email, or web to expedite resolution.”
• Of Chemistry’s two unicorns to date, Serval is the most recent (the other is Decagon — also a Shen-led deal).

Related

• serval
• series-a

---

Fundraise intel (2026-05-25)

Appended per the investor-intelligence build (Pass 1, CONFLICTED tier). Content above this line is unchanged. Sources: chemistry.vc (portfolio + team + 2026-predictions blog), PitchBook investor profile, serval blog, partner LinkedIn — double-verified (Claude WebSearch/WebFetch + Exa CLI). ⚠️ FOLLOWER-CONFLICTED via Serval.

Firm Profile

• What they back: Chemistry VC — founded 2024, San Francisco (the 2024 firm, NOT a chemistry/biotech fund). Leads seed and Series A; AI-applications-heavy, with infra/fintech and (newly) bio + prediction-markets themes. Portfolio: Decagon, Granola, Plaid, HashiCorp, Pave, Tennr, Datacurve, Serval, Didero, Assort Health, Pangolin, Nova Intelligence, ComfyUI, Weaver AI, Yuzu.
• Fund size / vintage: $350M Fund I (2024 vintage; first and only fund to date). Team ~20 people.
• Stage / check: Seed → Series A; “seeks to lead seed and Series A” (PitchBook) — but was a follower on the Serval conflict deal.
• Structure: 3 founding/managing partners + 2 investing team members (Ivory Tang, Bohan Lou). Small partnership → individual partner conviction drives deals.

Partners

• Kristina Shen — Co-Founder & Managing Partner. ⚠️ Owns the Serval conflict (Serval in her personal portfolio; deal partner ^[strongly inferred]). Ex-a16z (4y) + Bessemer (7y); strong AI-apps track record (Decagon, Sprig). The CRM POC.
• Ethan Kurzweil — Co-Founder & Managing Partner. Ex-Bessemer (16y). AI / open-source / dev-tools focus. Thesis-relevant rapport note: his Dec-2025 public 2026 prediction explicitly argues “computer-use agents… rendering forward-deployed engineering obsolete” and “computer-using agents automate full job functions” — i.e. the init.inc labor-automation / AI-employee thesis, stated by him publicly. Partner-clean of ITSM.
• Mark Goldberg — Co-Founder & Managing Partner. Ex-Index Ventures (8y, London). Fintech/infra (Plaid, Bridge, Pave, Persona, Lithic, Anrok). Partner-clean of ITSM; prediction-markets thesis for 2026.

Recent activity (Pass-1 sketch — full data → /Users/sazzad14/seed-market-scan/firms/chemistry-vc.csv)

• Serval — $47M Series A, Oct 21 2025, participated (follower) — THE CONFLICT DEAL (Redpoint led). ✅
• Decagon (CX agents, Jan 2026; Shen-led; Chemistry unicorn #2) — CX, not ITSM ⚠️ adjacency.
• Didero (agentic procurement, Feb 2026), Pangolin (seed, Aug 2025), Nova Intelligence (May 2026, most recent) — B2B-AI; amount/role single-source ⚠️.

Best data channels for this firm

• chemistry.vc/portfolio + per-partner team pages are the best primary source — each partner page lists their personal deal attributions (this is how the Serval→Shen link is established).
• chemistry.vc blog (“A Few Things We’re Watching in 2026”) + partner LinkedIn (Kurzweil @ethankurz, Goldberg @mark_goldberg_) = the thesis voice (strong for rapport hooks).
• PitchBook investor profile = the cleanest deal-list spine (14 investments listed), though it under-specifies lead-vs-participate and amounts. serval blog = the Serval conflict primary.

Fundraise Relationship (init.inc)

• Status: ⚠️ CONFLICTED (follower-grade) — relationship CLOSED. Chemistry was a follower (not lead) in Serval’s Series A. Per cap-table-patterns-across-startup-competitors, a follower conflict = “needs careful partner-mapping” (less internal pressure than a lead). The firm passed: init met Kristina Shen and hit a catch-22 (init can’t share product without an investment path; Kristina can’t decide without product). Firm has live Serval exposure + a closed prior conversation.
• Conversation log (newest first):
  • 2026-04-30 — CLOSED. “CONFLICTED — Chemistry invested in Serval. Met Kristina in person Wed 2026-04-29 2:00 PM at 421 Bryant St. Catch-22 surfaced: Sazzad can’t share product/strategy without a path to investment; Kristina can’t decide if she can invest without those details. No path forward.”
• Mutual connections / warm path: Raymond → Kristina Shen (the path used; conflicted/closed).
• Firm culture note: Thesis-forward, AI-operational (“2026 is the year AI becomes fully embedded… in the unwieldy backends of how businesses actually run” — Chemistry’s own framing, which overlaps init.inc’s wedge).
• Live stage: tracked in the CRM (Google Sheet) — Conflicted / Closed.

Cross-check vs existing wiki

• ✅ Consistent. The page above + cap-table-patterns-across-startup-competitors (line ~70) both record Chemistry as a Serval follower (not lead), deal partner Kristina Shen ^[strongly inferred]. No contradiction.
• ✅ Exposure scope confirmed (this build’s required check): swept Chemistry’s full portfolio (chemistry.vc + PitchBook, 14 deals) against all 8 init.inc competitors — Serval is the ONLY AI-ITSM conflict. Decagon (CX), Didero (procurement), Pangolin, Tennr, etc. are AI-app adjacencies, not direct ITSM/AI-MSP competitors. So Chemistry is single-competitor, follower-grade conflicted — the lightest of the three firms in this pod.

Related (this section)

• Kristina Shen · serval · cap-table-patterns-across-startup-competitors · index-ventures · bessemer-venture-partners

Pass 2 deal pattern (2026-05-25)

Pass-2 deal pull (CONFLICTED tier, MODERATE depth). Conflict-surface-first. Double-verified (Exa CLI + Claude WebSearch). Full data → /Users/sazzad14/seed-market-scan/firms/chemistry-vc.csv (8 rows). Content above this line unchanged.

Conflict surface (exhaustive — the priority)

Swept Chemistry’s full portfolio against all 16 init.inc competitors AND the close-adjacent surface (AI-ITSM / agentic-IT / back-office / services-as-software). Sources: chemistry.vc/portfolio + per-partner team pages, PitchBook, goldi.ai + parsers.vc trackers, Serval blog, partner LinkedIn, SaaStr.

• DIRECT competitor exposure = Serval ONLY — participated (FOLLOWER, not lead) in the $47M Series A (Oct 21, 2025; Redpoint led). Deal partner Kristina Shen ^[strongly inferred] (Serval in her personal portfolio). No change from Pass 1 — re-confirmed. Chemistry remains the LIGHTEST conflict of the three firms in this pod (follower-grade, single competitor).
• No other roster competitor found. Console, Atomicwork, STLabs, Edra, Treeline, Risotto, Ravenna, Echelon, Siit, Modern, QueryPal, Wrangle, Rezolve, ClearFeed, Unthread — all NO across chemistry.vc/portfolio + PitchBook + two third-party trackers. ✅
• Close-adjacents (services-as-software, but NONE are ITSM/IT-helpdesk): Decagon (CX/customer-support agents), Assort Health (healthcare front-office), Tennr (healthcare referral/document ops), Didero (agentic procurement), Anrok (sales-tax automation, fintech), Nova Intelligence (software-dev apps). Each is a different vertical — Chemistry’s thesis is AI-agents-across-business-functions, and the IT function is filled by Serval alone. So the adjacency density does NOT add a second ITSM conflict; it confirms Serval is the firm’s single IT bet.

Net conflict surface: single direct competitor (Serval), follower posture. Lightest of the pod.

Representative recent seed pattern (moderate)

Chemistry leads seed + Series A with $3–30Mchecks,average$10–12M (Kurzweil, SaaStr 2025), ~5–10 deals/year firm-wide, ~2–3 per GP/year, off a single $350M Fund I (2024 vintage). Concentrated, hands-on, no multi-stage scaling. Structurally decisive fact (firm-confirmed, double-verified): all three GPs are actively involved in EVERY investment decision — there is no junior-partner delegation; the trio acts as the portfolio-services team on each deal. This is the key Pass-2 finding for the clean-lane question (below).

Per-partner cap-table map

Partner	Cap-table conflict (ITSM)?
Kristina Shen (Co-Founder/MP)	⚠️ Owns the Serval follower conflict (personal portfolio). Was the CRM POC; the prior conversation hit a catch-22 and closed.
Ethan Kurzweil (Co-Founder/MP)	None — ex-Bessemer; AI/open-source/dev-tools. His Dec-2025 public 2026 prediction (“computer-use agents rendering forward-deployed engineering obsolete,” “computer-using agents automate full job functions”) overlaps init.inc’s labor-automation / AI-employee thesis.
Mark Goldberg (Co-Founder/MP)	None — ex-Index; fintech/infra (Plaid, Bridge, Pave, Persona, Lithic, Anrok); 2026 prediction-markets thesis.

Structural note: All three GPs are involved in every investment decision (no junior-partner delegation), so any Chemistry deal runs through Shen — who owns the Serval follower conflict. Kurzweil and Goldberg are clean of any ITSM cap-table tie (re-verified this pass).

Best data channel

chemistry.vc/portfolio + per-partner team pages (each lists personal deal attributions — how the Serval→Shen link is established). chemistry.vc blog + partner LinkedIn (Kurzweil @ethankurz, Goldberg @mark_goldberg_) for the thesis voice (rapport hooks). PitchBook + goldi.ai as the deal-list spine (under-specify lead-vs-participate). Serval blog = the conflict primary. SaaStr (Kurzweil) = the seed/Series-A check-size + market-cadence statement.

COULDN’T-GET

• Exact amounts/dates for several Chemistry adjacencies (Tennr, Didero, Nova Intelligence) — undisclosed or single-source PitchBook ⚠️. They are non-conflict (wrong vertical), so this does not affect the conflict-surface verdict.
• Decagon Series D ($250M/$4.5B val) and Assort Series B ($76M) are single-source (goldi.ai) ⚠️ — context only, both CX/healthcare, not ITSM.